시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 가성 장폐색 치료 시장 보고서(2024년)
Intestinal Pseudo Obstruction Treatment Global Market Report 2024
상품코드 : 1455257
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,274,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,911,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,549,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

가성 장폐색 치료 시장 규모는 향후 몇 년동안 크게 성장할 것으로 예상됩니다. 2028년까지 5.4%의 연평균 복합 성장률(CAGR)로 308억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 노인 인구 증가, 전 세계 호흡기 질환 증가, 신경 질환에 대한 적용 확대, 개인 맞춤형 의료 트렌드, 예방 의료에 대한 노력, 신흥 경제국 시장 침투 등 여러 가지 요인에 기인하는 것으로 보입니다. 예측 기간 동안 예상되는 주요 동향으로는 제제 기술의 발전, 소아 및 노인 대상 용도에 대한 관심 증가, 자가 투여 장치 증가, 비강용 분말 흡입기의 출현, 생물학적 제제 및 펩타이드의 통합 등이 있습니다.

위장관 질환의 유병률 증가가 예상됨에 따라 향후 몇 년동안 가성 장폐색증 치료제 시장의 성장을 가속할 것으로 예상됩니다. 소화기 질환으로 알려진 위장 질환은 입에서 항문까지 이어지는 위장관에 영향을 미치는 광범위한 증상을 포함합니다. 이러한 질환은 가성 장폐색을 포함한 다양한 합병증을 유발하기 때문에 관련 증상을 치료할 수 있는 효과적인 치료법 개발 및 제공의 필요성이 강조되고 있습니다. 일례로 미국암협회(ACS)는 2023년 1월 미국 내 소화기암 발병 건수가 3.18% 증가해 2021년 338,090건에서 348,840건으로 증가했다고 보고했습니다. 이러한 위장 질환의 유병률 증가는 위장관 질환 치료 시장 성장의 원동력이 되고 있습니다.

파킨슨병(PD)의 발병률 증가는 가까운 미래에 가성 장폐색증 치료제 시장 확대의 촉진제가 될 것으로 예측됩니다. 파킨슨병은 중추신경계에 영향을 미치는 만성 신경 퇴행성 질환으로 떨림, 경직, 운동 둔화, 자세 불안정 등의 증상이 나타나며, 변비, 장폐색과 같은 비운동성 증상을 동반합니다. 이 시나리오에서는 이러한 증상에 대처할 수 있는 효과적인 치료법의 개발과 제공이 필요합니다. 예를 들어, 파킨슨병 재단이 지원하는 2022년 연구 이니셔티브에 따르면 미국에서 매년 거의 9 만 명이 파킨슨병 진단을 받고 있으며, 이는 이전에 예상했던 연간 6 만 명의 진단율보다 50% 증가한 것으로 나타났습니다. 또한 파킨슨병(PD) 환자 인구는 2030년까지 120만 명에 달할 것으로 예상됩니다. 따라서 파킨슨병(PD) 유병률 증가는 가성 장폐색증 치료 시장의 성장을 가속하는 주요 요인이 될 것으로 보입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 가능성 분석

제36장 부록

LSH
영문 목차

영문목차

Intestinal pseudo-obstruction treatment involves medical interventions and therapies aimed at managing a rare condition characterized by the obstruction of the intestine (bowels) without any physical blockage. Symptoms of intestinal pseudo-obstruction include abdominal pain, bloating, nausea, and vomiting. The approach to treating chronic intestinal pseudo-obstruction includes adjustments to diet, nutrition assistance, medications, decompression, and other therapeutic measures.

The primary categories of conditions in intestinal pseudo-obstruction treatment are acute and chronic. Acute refers to the sudden onset or rapid development of symptoms or a medical condition. Various treatments, such as medication, surgery, diet adjustments, and others, are employed with diagnoses conducted through physical examination, biopsy, blood tests, gastric emptying tests, imaging tests, and other diagnostic methods. End users of these treatments include hospitals and clinics, ambulatory care centers, and other healthcare facilities.

The intestinal pseudo obstruction treatment market research report is one of a series of new reports from The Business Research Company that provides intestinal pseudo obstruction treatment market statistics, including intestinal pseudo obstruction treatment industry global market size, regional shares, competitors with a intestinal pseudo obstruction treatment market share, detailed intestinal pseudo obstruction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the intestinal pseudo obstruction treatment industry. This intestinal pseudo obstruction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestinal pseudo obstruction treatment market size has grown strongly in recent years. It will grow from $23.63 billion in 2023 to $24.98 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historical period can be attributed to several factors, including an increase in chronic respiratory diseases, heightened patient preference and compliance, the convenience of self-administration, expanded applications in pediatrics, market growth in allergic rhinitis treatment, and a broader range of indications.

The intestinal pseudo obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $30.87 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing geriatric population, a rise in global respiratory issues, expanding applications in neurological disorders, trends in personalized medicine, initiatives in preventive healthcare, and market penetration in emerging economies. Key trends expected in the forecast period include advancements in formulation technologies, a heightened focus on pediatric and geriatric applications, an increase in self-administration devices, the emergence of nasal powder inhalers, and the incorporation of biologics and peptides.

The anticipated rise in the prevalence of gastrointestinal diseases is poised to propel the expansion of the market for intestinal pseudo-obstruction treatment in the coming years. Gastrointestinal diseases, also known as digestive disorders, encompass a broad spectrum of conditions affecting the GI tract, the passage extending from the mouth to the anus. These diseases give rise to various complications, including intestinal pseudo-obstruction, emphasizing the need for the development and provision of effective treatments to address associated symptoms. As an illustration, in January 2023, the American Cancer Society (ACS) reported a 3.18% increase in gastrointestinal cancers in the United States, reaching 348,840 cases compared to 338,090 in 2021. This escalation in the prevalence of gastrointestinal diseases is expected to be a driving force behind the growth of the intestinal pseudo-obstruction treatment market.

The escalating incidence of Parkinson's disease (PD) is projected to be a catalyst for the expansion of the intestinal pseudo-obstruction treatment market in the foreseeable future. Parkinson's disease, characterized by chronic neurodegeneration affecting the central nervous system and manifesting in symptoms such as tremors, rigidity, bradykinesia, and postural instability, is associated with non-motor symptoms such as constipation and intestinal pseudo-obstruction. This scenario necessitates the development and provision of effective treatments to address these symptoms. For example, a 2022 research initiative supported by the Parkinson's Foundation revealed that nearly 90,000 individuals in the United States are diagnosed with Parkinson's disease annually, marking a 50% increase from the previously anticipated rate of 60,000 diagnoses per year. Furthermore, it is expected that the population of individuals with Parkinson's disease (PD) will reach 1.2 million by 2030. Hence, the rising incidence of Parkinson's disease (PD) is poised to be a key driver for the growth of the intestinal pseudo-obstruction market.

The anticipated high cost of treatment is poised to act as a hindrance to the growth of the intestinal pseudo-obstruction treatment market. The expected elevated expenses associated with treatment are likely to create barriers to accessibility, potentially limiting patient adoption due to financial constraints and economic considerations. As an illustration, data from Wellness Destination India.com in January 2023, an India-based medical tourism company, revealed that the cost for intestinal obstruction surgery in India for international patients ranged between USD 6,000 to USD 6,500, indicating a significant financial burden. Consequently, the substantial cost of treatment has the potential to impede the growth of the intestinal pseudo-obstruction treatment market.

Prominent companies within the intestinal pseudo-obstruction treatment market are actively engaged in the development of innovative drug therapies, such as NHE3 inhibitor treatment therapy, to offer reliable services to customers. NHE3 inhibitor treatment therapy involves medication that functions by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, introduced IBSRELA, an NHE3 inhibitor treatment designed for irritable bowel syndrome with constipation (IBS-C) in adults. This therapy holds the potential to enhance gastrointestinal motility. IBSRELA operates by inhibiting or blocking the activity of the Sodium-Hydrogen Exchanger 3 (NHE3) protein, leading to improved sodium and water absorption in the intestines and intestinal tract. This mechanism ultimately enhances gastrointestinal motility and alleviates symptoms associated with intestinal pseudo-obstruction.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic acquisition is poised to enhance Ironwood's innovation pipeline and overall portfolio, aiming to redefine the standard of care for patients with gastrointestinal (GI) conditions and advance the treatment of GI illnesses. VectivBio Holding AG, based in Switzerland, is a clinical-stage biotechnology company specializing in the treatment of severe and rare gastrointestinal conditions, including intestinal pseudo-obstruction (IPO).

Major companies operating in the intestinal pseudo obstruction treatment market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Olympus Corporation, Steris PLC, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Inc., Carestream Health, Ironwood Pharmaceuticals Inc., Fujifilm Healthcare Solutions, Basilea Pharmaceutica Ltd., Melinta Therapeutics LLC, VectivBio AG, Tetraphase Pharmaceuticals, Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo obstruction treatment market in 2023. The regions covered in the intestinal pseudo obstruction treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the intestinal pseudo-obstruction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestinal pseudo-obstruction treatment market consists of revenues earned by entities by providing diagnostic services such as metabolic panel tests, manometry, and serum electrolyte level tests that help in diagnosing and monitoring patients with intestinal pseudo-obstruction. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction market also includes sales of drug types such as antibiotics, antidepressants, and antidiarrheals that are used in treating intestinal pseudo-obstruction. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intestinal Pseudo Obstruction Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intestinal pseudo obstruction treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for intestinal pseudo obstruction treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intestinal pseudo obstruction treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Scope

Markets Covered:

Table of Contents

1. Executive Summary

2. Intestinal Pseudo Obstruction Treatment Market Characteristics

3. Intestinal Pseudo Obstruction Treatment Market Trends And Strategies

4. Intestinal Pseudo Obstruction Treatment Market - Macro Economic Scenario

5. Global Intestinal Pseudo Obstruction Treatment Market Size and Growth

6. Intestinal Pseudo Obstruction Treatment Market Segmentation

7. Intestinal Pseudo Obstruction Treatment Market Regional And Country Analysis

8. Asia-Pacific Intestinal Pseudo Obstruction Treatment Market

9. China Intestinal Pseudo Obstruction Treatment Market

10. India Intestinal Pseudo Obstruction Treatment Market

11. Japan Intestinal Pseudo Obstruction Treatment Market

12. Australia Intestinal Pseudo Obstruction Treatment Market

13. Indonesia Intestinal Pseudo Obstruction Treatment Market

14. South Korea Intestinal Pseudo Obstruction Treatment Market

15. Western Europe Intestinal Pseudo Obstruction Treatment Market

16. UK Intestinal Pseudo Obstruction Treatment Market

17. Germany Intestinal Pseudo Obstruction Treatment Market

18. France Intestinal Pseudo Obstruction Treatment Market

19. Italy Intestinal Pseudo Obstruction Treatment Market

20. Spain Intestinal Pseudo Obstruction Treatment Market

21. Eastern Europe Intestinal Pseudo Obstruction Treatment Market

22. Russia Intestinal Pseudo Obstruction Treatment Market

23. North America Intestinal Pseudo Obstruction Treatment Market

24. USA Intestinal Pseudo Obstruction Treatment Market

25. Canada Intestinal Pseudo Obstruction Treatment Market

26. South America Intestinal Pseudo Obstruction Treatment Market

27. Brazil Intestinal Pseudo Obstruction Treatment Market

28. Middle East Intestinal Pseudo Obstruction Treatment Market

29. Africa Intestinal Pseudo Obstruction Treatment Market

30. Intestinal Pseudo Obstruction Treatment Market Competitive Landscape And Company Profiles

31. Intestinal Pseudo Obstruction Treatment Market Other Major And Innovative Companies

32. Global Intestinal Pseudo Obstruction Treatment Market Competitive Benchmarking

33. Global Intestinal Pseudo Obstruction Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Intestinal Pseudo Obstruction Treatment Market

35. Intestinal Pseudo Obstruction Treatment Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기